Wyeth

Zoetis Services LLC

St. Jude Children's Research Hospital

Zoeits W LLC

Pah W LLC

Zoetis W LLC

Mahesh Kumar

Jeffrey Harold Rodenberg

Henry H Fan

Roberto Marcello La Ragione

Martin John Woodward

Evan James Diehl

Muhammad Ayub Khan

Kalen Cookson

David Leon Lutz

Paul Joseph Dominowski

John Morgan Hardham

Robert G Webster

Steven Alan Dunham

Erich Hoffmann

Richard John Webby

Duncan Mwangi

Dennis L Foss

Sharath K Rai

Eric Baima

Jason John Millership

Rut Vila-Quintana

Sharon Marie Wappel

Nicole Lynn Hainer

Yulia Burakova

Scott L Krauss

Juan Plana-Duran

Jordi Tarres-Call

The invention provides stable coronavirus spike proteins. Immunogenic compositions comprising same and the methods of using these immunogenic compositions are also provided.

Anti-coronavirus vaccines

A system for vaccinating swine according to one embodiment includes a housing having an open first end and an open opposite second end. The housing has a pair of side walls that are angled and non-parallel to one another such that at the second end only a single piglet can exit at one time. The system also includes a vaccination station for individually vaccinating piglets. The vaccination station is located between the pair of side walls in a region thereof that is sized to only permit one piglet to stand between the side walls. The vaccination station includes at least one sensor that detects the presence of the one piglet within the vaccination station and at least one spray nozzle positioned within the vaccination station such that a vaccine dose discharged therefrom is directed upwardly into facial areas of the piglet effectively.

Swine vaccination system

Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an oil phase in the presence of an emulsifier.

Emulsion vaccine compositions comprising antigen and adjuvant in the aqueous phase

A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.

Avian influenza viruses, vaccines, compositions, formulations, and methods

Antigenic isolates and vaccines for Infectious Bursal Disease Virus include variants of the molecular Group 6 family of IBDV isolates, in particular the 28-1 isolate.

Infectious bursal disease virus antigenic isolates and vaccines

The present invention provides live, attenuatedbacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-typebacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuatedbacteria, and methods for making live attenuatedbacteria. An exemplary live, attenuated strain ofis provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine againstinfection in chickens.

[object Object]

A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined haemoagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.

Multivalent avian influenza vaccines

A genetic deletion mutant livevaccine suitable for mass application to poultry, including chickens, is provided. Also provided is a safe and effective method to protect poultry against the ravages ofbacillosis infection and disease in which a live mutant aroA-gene deletedimmunogen is administered to chickens, turkeys and the like via mass application routes such as coarse sprays and drinking water.

There is provided a vaccine composition comprising a combination of a genetic deletion mutantmicroorganism and a genetic deletion mutantmicroorganism, suitable for mass application to poultry. Also provided is a safe and effective method to protect poultry against the ravages ofandinfection and disease.

Growing community of inventors

Fort Dodge, IA, United States of America

Mahesh Kumar